1. Share Prices

  2. Shield Therapeutics PLC (STX)

1.35p+0.13 (+10.20%)26 Apr 2024, 17:06
Find out how to deal online from £1.50 in a SIPP, ISA or Dealing account.AJ Bell logo
Jump to:

Shield Therapeutics PLC Fundamentals

Company NameShield Therapeutics PLCLast Updated2024-04-26
IndustryDrug Manufacturers - Specialty & GenericSectorHealthcare
Shares in Issue782.056 mMarket Cap£10.56 m
PE Ratio32.15Dividend per Share0
Dividend Yield0Dividend Cover0
EPS-£0.17EPS Growth (%)0
PEG0DPS Growth (%)0
Debt Ratio0.1385Debt Equity Ratio0.2105
Asset Equity Ratio1.5374Cash Equity Ratio0.5016
Quick Ratio2.5797Current Ratio2.95
Price To Book Value0.3535ROCE0

Shield Therapeutics PLC Dividends

TypeEx-DatePay DateCurrencyNet DividendYear Total

Shield Therapeutics PLC Company Financials

Assets20222021
Tangible Assets£197,000.00£304,000.00
Intangible Assets£11.78 m£26.85 m
Investments00
Total Fixed Assets£11.98 m£27.16 m
Stocks£1.46 m£1.64 m
Debtors£3.31 m£1.20 m
Cash & Equivalents£2.82 m£12.12 m
Other Assets00
Total Assets£22.07 m£44.41 m
Liabilities20222021
Creditors within 1 year£10.64 m£3.72 m
Creditors after 1 year£6.01 m0
Other Liabilities00
Total Liabilities£16.65 m£3.72 m
Net assets£5.43 m£40.69 m
Equity20222021
Called up share capital£3.89 m£3.24 m
Share Premium£116.26 m£114.58 m
Profit / Loss-£40.08 m-£19.91 m
Other Equity£5.43 m£40.69 m
Preference & Minorities00
Total Capital Employed£5.43 m£40.69 m
Ratios20222021
Debt Ratio£0.530
Debt-to-Equity£1.110
Assets / Equity1.53741.5374
Cash / Equity0.50160.5016
EPS-£0.12-£0.10
Cash Flow20222021
Cash from operating activities-£17.31 m-£18.26 m
Cashflow before financing-£10.30 m£9.45 m
Increase in Cash-£12.17 m£7.40 m
Income20222021
Turnover£4.47 m£1.52 m
Cost of sales£2.47 m£980,000.00
Gross Profit£2.00 m£539,000.00
Operating Profit-£40.41 m-£20.29 m
Pre-Tax profit-£40.08 m-£19.91 m

Shield Therapeutics PLC Company Background

SectorHealthcare
ActivitiesShield Therapeutics PLC is a specialty pharmaceutical company focused on the development and commercialization of late-stage, hospital-focused pharmaceuticals which address areas of high unmet medical need. The company's operating segmentsare based on key products including Accrufer/Feraccru, used as a novel oral treatment for iron deficiency anemia in patients, which is commercially available, and PT20 used in treating hyperphosphatemia, which is in its last stage of completion. The company generates maximum revenue from Feraccru segment.
Latest Interim Date28 Sep 2023
Latest Fiscal Year End Date30 Apr 2024

Shield Therapeutics PLC Directors

AppointedNamePosition
2023-11-27Mr. Hans Peter HaslerNon-Executive Director,Chairman
2018-06-27Dr. Andrew John William HeathNon-Executive Director,Chairman
2020-06-18Mr. James Michael KarisNon-Executive Director,Chairman
2022-07-01Mr. Timothy William WattsExecutive Director
2023-05-18Ms. Maria Fabiana Lacerca-AllenNon-Executive Director
2017-09-14Ms. Joanne Elizabeth EstellExecutive Director,Chief Financial Officer
2023-06-06Mr. Gregory Paul MadisonExecutive Director,Group Chief Executive Officer
2023-05-18Mr. Peter Hermann William Llewellyn-DaviesNon-Executive Director
2017-05-04Mr. Richard Crispin Morgan JonesExecutive Director,Chief Financial Officer and Company Secretary
2020-04-22Mr. Carl Andrew SterrittExecutive Director,Chief Executive Officer
2023-05-09Dr. Christian SchweigerNon-Executive Director
2023-05-18Mr. Karl Anders LundstromNon-Executive Director

Shield Therapeutics PLC Contact Details

Company NameShield Therapeutics PLC
AddressNorthern Design Centre Studio 6, 3rd Floor, Baltic Business Quarter, Newcastle, NE8 3DF
Telephone+44 1915118500
Websitehttps://www.shieldtherapeutics.com

Shield Therapeutics PLC Advisors

StockbrokerPeel Hunt LLP
Phone+44 2074188900
Remuneration ConsultantDeloitte LLP
Phone+44 2079363000
Fax+44 2075831198
AuditorKPMG
Phone(0191) 401 3700
Fax(0191) 401 3750
Financial PR AdviserConsilium Strategic Communications
Phone+44 2037095700
SolicitorStephenson Harwood
Phone+44 2073294422
Fax+44 2073297100
StockbrokerLiberum Capital Limited
Phone+44 2031002000
Fax+44 2031002299
RegistrarCapita Asset Services
Phone+44 8716640300
Fax+44 2086392342
Nominated AdviserLiberum Capital Limited
Phone+44 2031002000
Fax+44 2031002299

Receive our
daily news email

Subscribe to the latest investing news by entering your email address below

You can opt out at any time.

For five days a week you will get

  • The latest company news
  • Insight into investment trends
  • Round-up of director's buys and sells
  • Articles from Shares magazine
Sharesmagazine cover

Plus more useful investment content and occasional promotional offers.

Shares Magazine Latest Issue Cover
Latest Issue:
25 Apr 2024Subscribe now

Market Overview

UK 350 Risers and Fallers

Risers

CompanyPrice% Chg
Darktrace PLC602.0016.44
Travis Perkins PLC766.006.46
Natwest Group PLC307.406.07
Ashtead Group PLC6,104.005.97
Tritax Eurobox PLC53.804.87
Tbc Bank Group PLC3,450.004.39

Fallers

CompanyPrice% Chg
Convatec Group PLC257.80-6.46
Wh Smith PLC1,120.00-5.25
Beazley PLC638.00-3.11
Entain PLC784.20-3.09
Me Group International PLC162.80-2.75
Ocado Group PLC353.10-2.54
Risers/fallers data from previous trading day.